Purchase Of Shares In Pear Therapeutics Inc. (PEAR) By 5AM Partners IV, LLC

0
6
KOSK
KOSK

As of Wednesday close, Pear Therapeutics Inc.’s (NASDAQ:PEAR) stock was up $0.08, moving up 4.21 percent to $1.98. The average number of shares traded per day over the past five days has been 190,220 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0600 gain in that time frame. In the last twenty days, the average volume was 212,020, while in the previous 50 days, it was 395,864.

Since last month, PEAR stock retreated -26.39%. Shares of the company fell to $1.7700 on 11/21/22, the lowest level in the past month. A 52-week high of $14.60 was reached on 01/03/22 after having rallying from a 52-week low of $1.34. Since the beginning of this year, PEAR’s stock price has dropped by -68.06% or -$4.2200, and marked a new high 1 time. However, the stock has declined by -86.44% since its 52-week high.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


PEAR stock investors should be aware that Pear Therapeutics Inc. (PEAR) stock had its last reported insider trading activity 9 days ago on Nov 15. 5AM Partners IV, LLC, the 10% Owner of the company, disposed of 63,773 shares for $2.52 on Nov 15. It resulted in a $160,708 divestment by the insider. 5AM Partners IV, LLC sold 12,128 shares at an average price of $2.79 on Nov 14. The insider now owns 537,406 shares following the transaction. On Nov 11, 10% Owner 5AM Partners IV, LLC sold 29,380 shares at $3.19 apiece. The transaction was valued at $93,722.

Financial Health

In the three months ended June 29, Pear Therapeutics Inc.’s quick ratio stood at 2.10, while its current ratio was 2.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 55.10% percent. Based on annual data, PEAR earned -$1.02 million in gross profit and brought in $4.21 million in revenue.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PEAR’s revenue rose 100.0% to $3.3 million during the quarter, while net income inched up to $4.08 million. While analysts expected Pear Therapeutics Inc. to report -$0.25 quarterly earnings, the actual figure was $0.04 per share, beating the consensus estimate by 116.00%. During the quarter, the company generated -$25.06 million in EBITDA. The liabilities of Pear Therapeutics Inc. were 67.49 million at the end of its most recent quarter ended June 29, and its total debt was $38.39 million. The value of shareholders’ equity is $139.54 million.

Technical Picture

This quick technical analysis looks at Pear Therapeutics Inc.’s (PEAR) price momentum. With a historical volatility rate of 144.30%, the RSI 9-day stood at 37.92% on 23 November.

With respect to its five-day moving average, the current Pear Therapeutics Inc. price is up by +3.13% percent or $0.0600. At present, PEAR shares trade -29.54% below its 20-day simple moving average and +13.79% percent above its 100-day simple moving average. However, the stock is currently trading approximately +2.59% above its SMA50 and -56.39% below its SMA200.

Stochastic coefficient K was 7.91% and Stochastic coefficient D was 4.89%, while ATR was 0.2767. Given the Stochastic reading of 13.46% for the 14-day period, the RSI (14) reading has been calculated as 40.93%. As of today, the MACD Oscillator reading stands at -0.2522, while the 14-day reading stands at -0.4288.

Analyst Ratings

BofA Securities launched its rating on Pear Therapeutics Inc. (NASDAQ: PEAR) to a Neutral in a note to investors on January 26, 2022. Pear Therapeutics Inc. (PEAR) has been rated Overweight by analysts. According to 0 brokerage firms, PEAR is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Pear Therapeutics Inc. stock as buy, with 6 recommending it as overweight.

With a median target price of $5.00, the current consensus forecast for the stock is $2.80 – $8.00. Based on these forecasts, analysts predict Pear Therapeutics Inc. (PEAR) will achieve an average price target of $5.11.

LEAVE A REPLY

Please enter your comment!
Please enter your name here